[144] ANI Pharmaceuticals, Inc. SEC Filing
ANI Pharmaceuticals (ANIP) filed a Form 144 proposing the sale of 91,000 common shares. The shares are scheduled for an approximate sale date of 08/15/2025 through Morgan Stanley Smith Barney LLC and carry an aggregate market value of $7,866,267.50. The filing reports 21,688,772 shares outstanding, meaning the proposed sale represents a small fraction of total shares. The 91,000 shares were acquired on 11/19/2021 in exchange for convertible preferred shares and were paid for in cash on the acquisition date. No other sales in the prior three months were reported.
ANI Pharmaceuticals (ANIP) ha depositato un modulo 144 proponendo la vendita di 91.000 azioni ordinarie. La vendita è prevista intorno al 15/08/2025 tramite Morgan Stanley Smith Barney LLC e ha un valore di mercato complessivo di circa $7.866.267,50. Il deposito indica 21.688.772 azioni in circolazione, quindi l’operazione rappresenta una piccola porzione del capitale totale. Le 91.000 azioni sono state ottenute il 19/11/2021 in cambio di azioni privilegiate convertibili e sono state pagate in contanti alla data dell’acquisizione. Non risultano altre vendite nei tre mesi precedenti.
ANI Pharmaceuticals (ANIP) presentó un Formulario 144 proponiendo la venta de 91.000 acciones ordinarias. La venta está prevista aproximadamente para el 15/08/2025 a través de Morgan Stanley Smith Barney LLC y tiene un valor de mercado agregado de $7.866.267,50. El registro indica 21.688.772 acciones en circulación, por lo que la oferta constituye una fracción pequeña del total. Las 91.000 acciones se adquirieron el 19/11/2021 a cambio de acciones preferentes convertibles y se pagaron en efectivo en la fecha de adquisición. No se reportaron otras ventas en los tres meses anteriores.
ANI Pharmaceuticals(ANIP)는 91,000주 보통주 매각을 제안하는 Form 144를 제출했습니다. 해당 주식은 Morgan Stanley Smith Barney LLC를 통해 2025-08-15경에 매각될 예정이며 총 시가총액은 약 $7,866,267.50입니다. 제출서류에 따르면 발행주식수는 21,688,772주로, 제안된 매각물량은 전체의 극히 일부에 해당합니다. 이 91,000주는 2021-11-19에 전환우선주와의 교환으로 취득되었고 취득일에 현금으로 대금이 지급되었습니다. 직전 3개월 내 다른 매각은 보고되지 않았습니다.
ANI Pharmaceuticals (ANIP) a déposé un formulaire 144 proposant la vente de 91 000 actions ordinaires. La vente est prévue aux alentours du 15/08/2025 via Morgan Stanley Smith Barney LLC et représente une valeur de marché totale d’environ 7 866 267,50 $. Le dossier signale 21 688 772 actions en circulation, de sorte que l’opération constitue une faible part du capital total. Les 91 000 actions ont été acquises le 19/11/2021 en échange d’actions privilégiées convertibles et ont été réglées en espèces à la date d’acquisition. Aucune autre vente n’a été déclarée au cours des trois mois précédents.
ANI Pharmaceuticals (ANIP) hat ein Formular 144 eingereicht und den Verkauf von 91.000 Stammaktien vorgeschlagen. Der Verkauf ist für etwa den 15.08.2025 über Morgan Stanley Smith Barney LLC geplant und hat einen Gesamtmarktwert von rund $7.866.267,50. In der Einreichung werden 21.688.772 ausstehende Aktien angegeben, sodass der vorgeschlagene Verkauf nur einen kleinen Teil des Gesamtbestands darstellt. Die 91.000 Aktien wurden am 19.11.2021 im Tausch gegen wandelbare Vorzugsaktien erworben und am Erwerbsdatum in bar bezahlt. Innerhalb der vorangegangenen drei Monate wurden keine weiteren Verkäufe gemeldet.
- Clear compliance disclosure: The filer provides required Rule 144 details including broker, acquisition date, basis of acquisition, aggregate market value, and approximate sale date.
- None.
Insights
TL;DR: Insider plans to sell 91,000 ANIP shares (~$7.87M) acquired via convertible preferreds in 2021; filing follows Rule 144 disclosure requirements.
The Form 144 discloses a proposed sale executed through Morgan Stanley Smith Barney LLC with an approximate sale date of 08/15/2025. The position was originally acquired on 11/19/2021 via convertible preferred shares and paid in cash, which is relevant for determining resale eligibility under Rule 144. The disclosed aggregate market value ($7.87M) and the stated shares outstanding (21,688,772) allow market participants to gauge the sale's relative size; the sale represents a modest percentage of outstanding shares.
TL;DR: The filer provided required attestation and signature language; no undisclosed material information is claimed.
The filing includes the standard attestation that the seller is not aware of any undisclosed material adverse information about the issuer and notes the Rule 10b5-1 trading plan language if applicable. The submission identifies the broker and confirms there were no related sales in the prior three months. From a governance and disclosure standpoint, the filing appears procedurally complete for a Rule 144 notice.
ANI Pharmaceuticals (ANIP) ha depositato un modulo 144 proponendo la vendita di 91.000 azioni ordinarie. La vendita è prevista intorno al 15/08/2025 tramite Morgan Stanley Smith Barney LLC e ha un valore di mercato complessivo di circa $7.866.267,50. Il deposito indica 21.688.772 azioni in circolazione, quindi l’operazione rappresenta una piccola porzione del capitale totale. Le 91.000 azioni sono state ottenute il 19/11/2021 in cambio di azioni privilegiate convertibili e sono state pagate in contanti alla data dell’acquisizione. Non risultano altre vendite nei tre mesi precedenti.
ANI Pharmaceuticals (ANIP) presentó un Formulario 144 proponiendo la venta de 91.000 acciones ordinarias. La venta está prevista aproximadamente para el 15/08/2025 a través de Morgan Stanley Smith Barney LLC y tiene un valor de mercado agregado de $7.866.267,50. El registro indica 21.688.772 acciones en circulación, por lo que la oferta constituye una fracción pequeña del total. Las 91.000 acciones se adquirieron el 19/11/2021 a cambio de acciones preferentes convertibles y se pagaron en efectivo en la fecha de adquisición. No se reportaron otras ventas en los tres meses anteriores.
ANI Pharmaceuticals(ANIP)는 91,000주 보통주 매각을 제안하는 Form 144를 제출했습니다. 해당 주식은 Morgan Stanley Smith Barney LLC를 통해 2025-08-15경에 매각될 예정이며 총 시가총액은 약 $7,866,267.50입니다. 제출서류에 따르면 발행주식수는 21,688,772주로, 제안된 매각물량은 전체의 극히 일부에 해당합니다. 이 91,000주는 2021-11-19에 전환우선주와의 교환으로 취득되었고 취득일에 현금으로 대금이 지급되었습니다. 직전 3개월 내 다른 매각은 보고되지 않았습니다.
ANI Pharmaceuticals (ANIP) a déposé un formulaire 144 proposant la vente de 91 000 actions ordinaires. La vente est prévue aux alentours du 15/08/2025 via Morgan Stanley Smith Barney LLC et représente une valeur de marché totale d’environ 7 866 267,50 $. Le dossier signale 21 688 772 actions en circulation, de sorte que l’opération constitue une faible part du capital total. Les 91 000 actions ont été acquises le 19/11/2021 en échange d’actions privilégiées convertibles et ont été réglées en espèces à la date d’acquisition. Aucune autre vente n’a été déclarée au cours des trois mois précédents.
ANI Pharmaceuticals (ANIP) hat ein Formular 144 eingereicht und den Verkauf von 91.000 Stammaktien vorgeschlagen. Der Verkauf ist für etwa den 15.08.2025 über Morgan Stanley Smith Barney LLC geplant und hat einen Gesamtmarktwert von rund $7.866.267,50. In der Einreichung werden 21.688.772 ausstehende Aktien angegeben, sodass der vorgeschlagene Verkauf nur einen kleinen Teil des Gesamtbestands darstellt. Die 91.000 Aktien wurden am 19.11.2021 im Tausch gegen wandelbare Vorzugsaktien erworben und am Erwerbsdatum in bar bezahlt. Innerhalb der vorangegangenen drei Monate wurden keine weiteren Verkäufe gemeldet.